COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models - Institut Pasteur Access content directly
Journal Articles Nature Communications Year : 2021

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Yoann Aldon
Virginie Chesnais
  • Function : Author
Ségolène Diry
  • Function : Author
Anton Iershov
  • Function : Author
Adam Ronk
Jelle van Schooten
Mitch Brinkkemper
  • Function : Author
Chad Mire
Mariëlle van Breemen
  • Function : Author
Catherine Chapon
  • Function : Author
Raphaël Ho Tsong Fang
  • Function : Author
Charlene Mcdanal
  • Function : Author
Mary Osei-Twum
  • Function : Author
Natalie St-Amant
  • Function : Author
Luc Gagnon
  • Function : Author
David Montefiori
  • Function : Author
Ian Wilson
Eric Ginoux
  • Function : Author
Godelieve de Bree
  • Function : Author
Adolfo García-Sastre
Michael Schotsaert
Lynda Coughlan

Abstract

Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the in vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent against the B.1.1.7 isolate. In both prophylactic and therapeutic settings, SARS-CoV-2 remains undetectable in the lungs of treated hACE2 mice. Therapeutic treatment also causes a reduction in viral loads in the lungs of Syrian hamsters. When administered at 10 mg kg-1 one day prior to a high dose SARS-CoV-2 challenge in cynomolgus macaques, COVA1-18 shows very strong antiviral activity in the upper respiratory compartments. Using a mathematical model, we estimate that COVA1-18 reduces viral infectivity by more than 95% in these compartments, preventing lymphopenia and extensive lung lesions. Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation.
Fichier principal
Vignette du fichier
s41467-021-26354-0.pdf (1.19 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

pasteur-04098221 , version 1 (15-05-2023)

Licence

Attribution

Identifiers

Cite

Pauline Maisonnasse, Yoann Aldon, Aurélien Marc, Romain Marlin, Nathalie Dereuddre-Bosquet, et al.. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nature Communications, 2021, 12 (1), pp.6097. ⟨10.1038/s41467-021-26354-0⟩. ⟨pasteur-04098221⟩
16 View
49 Download

Altmetric

Share

Gmail Facebook X LinkedIn More